JP2025503707A5 - - Google Patents

Info

Publication number
JP2025503707A5
JP2025503707A5 JP2024542044A JP2024542044A JP2025503707A5 JP 2025503707 A5 JP2025503707 A5 JP 2025503707A5 JP 2024542044 A JP2024542044 A JP 2024542044A JP 2024542044 A JP2024542044 A JP 2024542044A JP 2025503707 A5 JP2025503707 A5 JP 2025503707A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
seq
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/051100 external-priority patent/WO2023139107A1/en
Publication of JP2025503707A publication Critical patent/JP2025503707A/ja
Publication of JP2025503707A5 publication Critical patent/JP2025503707A5/ja
Pending legal-status Critical Current

Links

JP2024542044A 2022-01-18 2023-01-18 ガレクチン－１０抗体 Pending JP2025503707A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202200597 2022-01-18
GB2200597.9 2022-01-18
PCT/EP2023/051100 WO2023139107A1 (en) 2022-01-18 2023-01-18 Galectin-10 antibodies

Publications (2)

Publication Number Publication Date
JP2025503707A JP2025503707A (ja) 2025-02-04
JP2025503707A5 true JP2025503707A5 (https=) 2026-03-03

Family

ID=85037098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542044A Pending JP2025503707A (ja) 2022-01-18 2023-01-18 ガレクチン－１０抗体

Country Status (10)

Country Link
US (1) US20250059285A1 (https=)
EP (1) EP4466070A1 (https=)
JP (1) JP2025503707A (https=)
KR (1) KR20240133711A (https=)
CN (1) CN118488967A (https=)
AU (1) AU2023208882A1 (https=)
CA (1) CA3236108A1 (https=)
IL (1) IL314367A (https=)
MX (1) MX2024006275A (https=)
WO (1) WO2023139107A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118206657B (zh) * 2023-12-29 2025-03-07 康旭生物科技(深圳)有限公司 一种半乳糖凝集素-3的抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
SG11201605203UA (en) 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
AU2019250689A1 (en) 2018-04-13 2020-10-08 Universiteit Gent Galectin-10 antibodies

Similar Documents

Publication Publication Date Title
JP2025111463A5 (https=)
JP2021520825A5 (https=)
JP2021526022A5 (https=)
RU2018112243A (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
JP2023093753A5 (https=)
CN111615519B (zh) 结合人il-5的单克隆抗体、其制备方法和用途
JP2020537520A5 (https=)
JP2022122865A5 (https=)
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2025501775A5 (https=)
JP2015503909A5 (https=)
JP2020522280A5 (https=)
TW202321300A (zh) Il-11人源化抗體及其應用
JP2024540148A5 (https=)
JP2023545183A5 (https=)
JP2023545182A5 (https=)
RU2017104638A (ru) Нейтрализующие антитела к вирусу гриппа B и пути их применения
CN106565840A (zh) 抗乙肝表面抗原的抗体及其用途
JP2022548646A5 (https=)
TWI853912B (zh) 包含抗il-5抗體的醫藥組成物及其用途
JP2023508674A5 (https=)
JP2025503707A5 (https=)
WO2024131949A1 (zh) Anti-cMet抗体、抗体药物偶联物及其制备方法和用途
CN115315442B (zh) Sars-cov-2抗体及其应用
JPWO2022044573A5 (https=)